Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials
Aim: To assess the effects of once-weekly subcutaneous retatrutide on weight and metabolic markers and the occurrence of side effects in patients with overweight, obesity and/or type 2 diabetes (T2D). Methods: PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically sea...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Metabolism Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589936824000537 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850246894267138048 |
|---|---|
| author | Eric Pasqualotto Rafael Oliva Morgado Ferreira Matheus Pedrotti Chavez Alexandre Hohl Marcelo Fernando Ronsoni Tales Pasqualotto Francisco Cezar Aquino de Moraes Larissa Hespanhol Janine Midori Figueiredo Watanabe Carine Lütkemeyer Simone van de Sande-Lee |
| author_facet | Eric Pasqualotto Rafael Oliva Morgado Ferreira Matheus Pedrotti Chavez Alexandre Hohl Marcelo Fernando Ronsoni Tales Pasqualotto Francisco Cezar Aquino de Moraes Larissa Hespanhol Janine Midori Figueiredo Watanabe Carine Lütkemeyer Simone van de Sande-Lee |
| author_sort | Eric Pasqualotto |
| collection | DOAJ |
| description | Aim: To assess the effects of once-weekly subcutaneous retatrutide on weight and metabolic markers and the occurrence of side effects in patients with overweight, obesity and/or type 2 diabetes (T2D). Methods: PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched for placebo-controlled, randomized clinical trials (RCTs) published up until February 23, 2024. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) for binary endpoints were computed, with 95 % confidence intervals (CIs). Results: A total of three studies were included, comprising 640 patients, of whom 510 were prescribed retatrutide. Compared with placebo, retatrutide significantly reduced body weight (WMD -10.66 kg; 95 % CI -17.63, −3.69), body mass index (WMD -4.53 kg/m2; 95 % CI -7.51, −1.55), and waist circumference (WMD -6.61 cm; 95 % CI -13.17, −0.05). In addition, retatrutide significantly increased the proportion of patients who achieved a weight reduction of ≥5 % (RR 2.92; 95 % CI 2.17–3.93), ≥10 % (RR 9.32; 95 % CI 4.56–19.06), ≥15 % (RR 18.40; 95 % CI 6.00–56.42), and ≥20 % (RR 16.61; 95 % CI 4.17–66.12). Conclusions: In this meta-analysis, the use of once-weekly subcutaneous retatrutide was associated with a significant reduction in body weight and improvement of metabolic markers in patients with overweight, obesity and/or T2D, compared with placebo, with an increase in non-severe gastrointestinal and hypersensitivity adverse events. Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-weekly subcutaneous retatrutide over the long term. |
| format | Article |
| id | doaj-art-9dfce746a63c46d192f543d55753de9d |
| institution | OA Journals |
| issn | 2589-9368 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Metabolism Open |
| spelling | doaj-art-9dfce746a63c46d192f543d55753de9d2025-08-20T01:59:04ZengElsevierMetabolism Open2589-93682024-12-012410032110.1016/j.metop.2024.100321Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trialsEric Pasqualotto0Rafael Oliva Morgado Ferreira1Matheus Pedrotti Chavez2Alexandre Hohl3Marcelo Fernando Ronsoni4Tales Pasqualotto5Francisco Cezar Aquino de Moraes6Larissa Hespanhol7Janine Midori Figueiredo Watanabe8Carine Lütkemeyer9Simone van de Sande-Lee10Department of Medicine, Federal University of Santa Catarina, Florianópolis, Brazil; Corresponding author. Campus Universitário, Rua Professora Maria Flora Pausewang, s/nº, Trindade, 88036-800, Florianópolis, SC, Brazil.Department of Medicine, Federal University of Santa Catarina, Florianópolis, BrazilDepartment of Medicine, Federal University of Santa Catarina, Florianópolis, BrazilDepartment of Medicine, Federal University of Santa Catarina, Florianópolis, BrazilDepartment of Medicine, Federal University of Santa Catarina, Florianópolis, BrazilDepartment of Medicine, Universidade Alto Vale do Rio do Peixe, Caçador, BrazilDepartment of Medicine, Federal University of Pará, Belém, BrazilDepartment of Medicine, Federal University of Campina Grande, Campina Grande, BrazilDepartment of Medicine, State University of Piauí, Teresina, BrazilIndependent Researcher, Florianópolis, SC, BrazilDepartment of Medicine, Federal University of Santa Catarina, Florianópolis, BrazilAim: To assess the effects of once-weekly subcutaneous retatrutide on weight and metabolic markers and the occurrence of side effects in patients with overweight, obesity and/or type 2 diabetes (T2D). Methods: PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were systematically searched for placebo-controlled, randomized clinical trials (RCTs) published up until February 23, 2024. Weighted mean differences (WMDs) for continuous outcomes and risk ratios (RRs) for binary endpoints were computed, with 95 % confidence intervals (CIs). Results: A total of three studies were included, comprising 640 patients, of whom 510 were prescribed retatrutide. Compared with placebo, retatrutide significantly reduced body weight (WMD -10.66 kg; 95 % CI -17.63, −3.69), body mass index (WMD -4.53 kg/m2; 95 % CI -7.51, −1.55), and waist circumference (WMD -6.61 cm; 95 % CI -13.17, −0.05). In addition, retatrutide significantly increased the proportion of patients who achieved a weight reduction of ≥5 % (RR 2.92; 95 % CI 2.17–3.93), ≥10 % (RR 9.32; 95 % CI 4.56–19.06), ≥15 % (RR 18.40; 95 % CI 6.00–56.42), and ≥20 % (RR 16.61; 95 % CI 4.17–66.12). Conclusions: In this meta-analysis, the use of once-weekly subcutaneous retatrutide was associated with a significant reduction in body weight and improvement of metabolic markers in patients with overweight, obesity and/or T2D, compared with placebo, with an increase in non-severe gastrointestinal and hypersensitivity adverse events. Phase 3 RCTs are expected to shed further light on the efficacy and safety of once-weekly subcutaneous retatrutide over the long term.http://www.sciencedirect.com/science/article/pii/S2589936824000537RetatrutideBody weightObesityMetabolism |
| spellingShingle | Eric Pasqualotto Rafael Oliva Morgado Ferreira Matheus Pedrotti Chavez Alexandre Hohl Marcelo Fernando Ronsoni Tales Pasqualotto Francisco Cezar Aquino de Moraes Larissa Hespanhol Janine Midori Figueiredo Watanabe Carine Lütkemeyer Simone van de Sande-Lee Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials Metabolism Open Retatrutide Body weight Obesity Metabolism |
| title | Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials |
| title_full | Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials |
| title_short | Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials |
| title_sort | effects of once weekly subcutaneous retatrutide on weight and metabolic markers a systematic review and meta analysis of randomized controlled trials |
| topic | Retatrutide Body weight Obesity Metabolism |
| url | http://www.sciencedirect.com/science/article/pii/S2589936824000537 |
| work_keys_str_mv | AT ericpasqualotto effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT rafaelolivamorgadoferreira effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT matheuspedrottichavez effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT alexandrehohl effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT marcelofernandoronsoni effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT talespasqualotto effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT franciscocezaraquinodemoraes effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT larissahespanhol effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT janinemidorifigueiredowatanabe effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT carinelutkemeyer effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT simonevandesandelee effectsofonceweeklysubcutaneousretatrutideonweightandmetabolicmarkersasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |